Package leaflet: Information for the user

ECALTA 100 mg powder for concentrate for solution for infusion

Anidulafungin

Read all of this leaflet carefully before you or your child start using this medicine because it contains important information for you.

• Keep this leaflet. You may need to read it again.

• If you have any further questions, ask your doctor or pharmacist or nurse.

• If you or your child get any side effects, talk to your doctor, or pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4.

  
  

  What is in this leaflet:

  
  

  1. What ECALTA is and what it is used for

  2. What you need to know before you or your child use ECALTA

  3. How to use ECALTA

  4. Possible side effects

  5. How to store ECALTA

  6. Contents of the pack and other information

  
  

  1. What ECALTA is and what it is used for

     
     

     ECALTA contains the active substance anidulafungin and is prescribed in adults and in paediatric patients aged 1 month to less than 18 years to treat a type of fungal infection of the blood or other internal organs called invasive candidiasis. The infection is caused by fungal cells (yeasts) called Candida.

     
     

     ECALTA belongs to a group of medicines called echinocandins. These medicines are used to treat serious fungal infections.

     
     

     ECALTA prevents normal development of fungal cell walls. In the presence of ECALTA, fungal cells have incomplete or defective cell walls, making them fragile or unable to grow.

     
     

  2. What you need to know before you or your child use ECALTA Do not use ECALTA

• if you are allergic to anidulafungin, other echinocandins (e.g. caspofungin acetate), or any of the other ingredients of this medicine (listed in section 6).

  
  

  Warnings and precautions

  Talk to your doctor or pharmacist or nurse before using ECALTA. Your doctor may decide to monitor you

• for liver function more closely if you develop liver problems during your treatment

• if you are given anaesthetics during your treatment with ECALTA

• for signs of an allergic reaction such as itching, wheezing, blotchy skin

• for signs of an infusion–related reaction which could include a rash, hives, itching, redness

• for shortness of breath/breathing difficulties, dizziness or lightheadedness

  
  

  Children and adolescents

  
  

  ECALTA should not be given to patients under 1 month of age.

  Other medicines and ECALTA

  
  

  Tell your doctor or pharmacist if you or your child are taking, have recently taken or might take any other medicines.

  
  

  Pregnancy and breast-feeding

  
  

  The effect of ECALTA in pregnant women is not known. Therefore, ECALTA is not recommended during pregnancy. Effective contraception should be used in women of childbearing age. Contact your doctor immediately if you become pregnant while taking ECALTA.

  
  

  The effect of ECALTA in breast-feeding women is not known. Ask your doctor or pharmacist for advice before taking ECALTA while breast-feeding.

  
  

  Ask your doctor or pharmacist for advice before taking any medicines.

  
  

  ECALTA contains fructose

  
  

  This medicine contains 119 mg fructose (a type of sugar) in each vial. If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicinal product.

  
  

  If you (or your child) have hereditary fructose intolerance (HFI), a rare genetic disorder, you (or your child) must not receive this medicine. Patients with HFI cannot break down fructose in this medicine, which may cause serious side effects.

  
  

  You must tell your doctor before receiving this medicine if you (or your child) have HFI or if your child can no longer take sweet foods or drinks because they feel sick, vomit or get unpleasant effects such as bloating, stomach cramps or diarrhoea.

  
  

  ECALTA contains sodium

  
  

  This medicine contains less than 1 mmol sodium (23 mg) per vial, that is to say essentially ‘sodium-free’.

  
  

  1. How to use ECALTA

     
     

     ECALTA will always be prepared and given to you or your child by a doctor or a healthcare professional (there is more information about the method of preparation at the end of the leaflet in the section for medical and healthcare professionals only).

     
     

     For use in adults, the treatment starts with 200 mg on the first day (loading dose). This will be followed by a daily dose of 100 mg (maintenance dose).

     
     

     For use in children and adolescents (age from 1 month to less than 18 years), the treatment starts with

     3.0 mg/kg (not to exceed 200 mg) on the first day (loading dose). This will be followed by a daily dose of 1.5 mg/kg (not to exceed 100 mg) (maintenance dose). The dose that is given depends on the patient’s weight.

     
     

     ECALTA should be given to you once a day, by slow infusion (a drip) into your vein. For adults, this will take at least 1.5hoursforthemaintenancedoseand3hoursfortheloadingdose. For children and adolescents, the infusion may take less time depending on the patient’s weight.

     
     

     Your doctor will determine the duration of your treatment and how much ECALTA you will receive each day and will monitor your response and condition.

     In general, your treatment should continue for at least 14 days after the last day Candida was found in your blood.

     
     

     If you receive more ECALTA than you should

     
     

     If you are concerned that you may have been given too much ECALTA, tell your doctor or another healthcare professional immediately.

     
     

     If you forgot to use ECALTA

     
     

     As you will be given this medicine under close medical supervision, it is unlikely that a dose would be missed. However tell your doctor or pharmacist if you think that a dose has been forgotten.

     
     

     You should not be given a double dose by doctor.

     
     

     If you stop using ECALTA

     You should not experience any effects from ECALTA if your doctor stops ECALTA treatment. Your doctor may prescribe another medicine following your treatment with ECALTA to continue

     treating your fungal infection or prevent it from returning.

     
     

     If your original symptoms come back, tell your doctor or another healthcare professional immediately. If you have any further questions on the use of this medicine, ask your doctor, or pharmacist or nurse.

     
     

  2. Possible side effects

     
     

     Like all medicines, this medicine can cause side effects, although not everybody gets them. Some of these side effects will be noted by your doctor while monitoring your response and condition.

     
     

     Life-threatening allergic reactions that might include difficulty breathing with wheezing or worsening of an existing rash have been rarely reported during administration of ECALTA.

     
     

     Serious side effects – tell your doctor or another healthcare professional immediately should any of the following occur:

• Convulsion (seizure)

• Flushing

• Rash, pruritis (itching)

• Hot flush

• Hives

• Sudden contraction of the muscles around the airways resulting in wheezing or coughing

• Difficulty of breathing

  
  

  Other side effects

  
  

  Very common side effects (may affect more than 1 in 10 people) are:

  
  

• Low blood potassium (hypokalaemia)

• Diarrhoea

• Nausea

  Common side effects (may affect up to 1 in 10 people) are:

  
  

• Convulsion (seizure)

• Headache

• Vomiting

• Changes in blood tests of liver function

• Rash, pruritis (itching)

• Changes in blood tests of kidney function

• Abnormal flow of bile from the gallbladder into the intestine (cholestasis)

• High blood sugar

• High blood pressure

• Low blood pressure

• Sudden contraction of the muscles around the airways resulting in wheezing or coughing

• Difficulty of breathing

  
  

  Uncommon side effects (may affect up to 1 in 100 people) are:

  
  

• Disorder of blood clotting system

• Flushing

• Hot flush

• Stomach pain

• Hives

• Pain at injection site

  
  

  Not known (frequency cannot be estimated from the available data) are:

  
  

• Life-threatening allergic reactions

  
  

  Reporting of side effects

  

  If you get any side effects, talk to your doctor or, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via thenationalreporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.

  
  

  1. How to store ECALTA

     
     

     Keep this medicine out of the sight and reach of children.

     
     

     Do not use this medicine after the expiry date which is stated on the label. The expiry date refers to the last day of that month.

     
     

     Store in a refrigerator (2C – 8C).

     
     

     The reconstituted solution may be stored up to 25C for up to 24 hours. The infusion solution may be stored at 25°C (room temperature) for 48 hours (do not freeze) and should be administered at 25C (room temperature) within 48 hours.

     
     

     Do not throw away any medicines via wastewater or household waste.

  2. Contents of the pack and other information What ECALTA contains

• The active substance is anidulafungin. Each vial of powder contains 100 mg anidulafungin.

• The other ingredients are: fructose (see section 2 “ECALTA contains fructose”), mannitol, polysorbate 80, tartaric acid, sodium hydroxide (for pH-adjustment) (see section 2 “ECALTA contains sodium”), hydrochloric acid (for pH-adjustment)

What ECALTA looks like and contents of the pack

ECALTA is supplied as a box containing 1 vial of 100 mg powder for concentrate for solution for infusion.

The powder is white to off-white.

Marketing Authorisation Holder

Pfizer Europe MA EEIG, Boulevard de la Plaine 17, 1050 Bruxelles, Belgium

Manufacturer

Pfizer Manufacturing Belgium NV, Rijksweg 12, 2870 Puurs, Belgium

For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:

België/Belgique/Belgien Luxembourg/Luxemburg Pfizer NV/SA

Tél/Tel: +32 (0)2 554 62 11

Lietuva

Pfizer Luxembourg SARL filialas Lietuvoje

Tel. +3705 2514000

България

Пфайзер Люксембург САРЛ, Клон България Тел.: +359 2 970 4333

Magyarország

Pfizer Kft.

Tel. + 36 1 488 37 00

Česká republika

Pfizer, spol. s r.o.

Tel: +420-283-004-111

Danmark

Pfizer ApS

Tlf: +45 44 20 11 00

Malta

Vivian Corporation Ltd. Tel : +356 21344610

Nederland

Pfizer bv

Tel: +31 (0)10 406 43 01

Deutschland

PFIZER PHARMA GmbH Tel: +49 (0)30 550055-51000

Norge

Pfizer AS

Tlf: +47 67 52 61 00

Eesti

Pfizer Luxembourg SARL Eesti filiaal Tel: +372 666 7500

Österreich

Pfizer Corporation Austria Ges.m.b.H. Tel: +43 (0)1 521 15-0

Ελλάδα

Pfizer ΕΛΛΑΣ A.E. Τηλ.: +30 210 6785 800

Polska

Pfizer Polska Sp. z o.o., Tel.: +48 22 335 61 00

España

Pfizer, S.L.

Tel: +34 91 490 99 00

Portugal

Laboratórios Pfizer, Lda. Tel: + 351 214 235 500

France

Pfizer

Tél: +33 (0)1 58 07 34 40

România

Pfizer România S.R.L Tel: +40 (0)21 207 28 00

Hrvatska

Pfizer Croatia d.o.o.

Tel: + 385 1 3908 777

Ireland

Pfizer Healthcare Ireland Tel: 1800 633 363 (toll free)

Tel: +44 (0)1304 616161

Slovenija

Pfizer Luxembourg SARL

Pfizer, podružnica za svetovanje s področja farmacevtske dejavnosti, Ljubljana

Tel: + 386 (0)152 11 400

Slovenská republika

Pfizer Luxembourg SARL, organizačná zložka Tel: +421-2-3355 5500

Ísland

Icepharma hf.,

Sími: + 354 540 8000

Suomi/Finland

Pfizer Oy

Puh/Tel: +358(0)9 43 00 40

Italia

Pfizer S.r.l.

Tel: +39 06 33 18 21

Sverige

Pfizer AB

Tel: +46 (0)8 5505 2000

Kύπρος

Pfizer ΕΛΛΑΣ Α.Ε. (Cyprus Branch) Τηλ: +357 22 817690

United Kingdom (Northern Ireland)

Pfizer Limited

Tel: +44 (0)1304 616161

Latvija

Pfizer Luxembourg SARL Filiāle Latvijā

Tel: +371 670 35 775

This leaflet was last revised in {MM/YYYY}.

.

--------------------------------------------------------------------------------------------------------------------------

The following information is intended for medical or healthcare professionals only and applies only to the single vial ECALTA 100 mg powder for concentrate for solution for infusion presentation:

The contents of the vial must be reconstituted with water for injection and subsequently diluted with ONLY 9 mg/mL (0.9%) sodium chloride for infusion or 50 mg/mL (5%) glucose for infusion. The compatibility of reconstituted ECALTA with intravenous substances, additives, or medicines other than 9 mg/mL (0.9%) sodium chloride for infusion or 50 mg/mL (5%) glucose for infusion has not been established. The infusion solution must not be frozen.

Reconstitution

Aseptically reconstitute each vial with 30 mL water for injection to provide a concentration of

1. mg/mL. The reconstitution time can be up to 5 minutes. After subsequent dilution, the solution is to be discarded if particulate matter or discolouration is identified.

   The reconstituted solution may be stored up to 25°C for up to 24 hours prior to further dilution.

   
   

   Dilution and infusion

   Parenteral medicinal products should be inspected visually for particulate matter and discolouration prior to administration, whenever solution and container permit. If either particulate matter or discolouration is identified, discard the solution.

   
   

   Adult Patients

   
   

   Aseptically transfer the contents of the reconstituted vial(s) into an intravenous bag (or bottle) containing either 9 mg/mL (0.9%) sodium chloride for infusion or 50 mg/mL (5%) glucose for infusion to obtain the appropriate anidulafungin concentration. The table below provides the dilution to a concentration of 0.77 mg/mL for the final infusion solution and infusion instructions for each dose.

   
   

   Dilution requirements for ECALTA administration

   
   

   Dose	Number of vials of powder	Total reconstituted volume	Infusion volume A	Total infusion volume B	Rate of infusion	Minimum duration of infusion
   100 mg	1	30 mL	100 mL	130 mL	1.4 mL/ min or 84 mL/ hour	90 min
   200 mg	2	60 mL	200 mL	260 mL	1.4 mL/ min or 84 mL/ hour	180 min

   A Either 9 mg/mL (0.9%) sodium chloride for infusion or 50 mg/mL (5%) glucose for infusion.

   B Infusion solution concentration is 0.77 mg/mL

   
   

   The rate of infusion should not exceed 1.1 mg/min (equivalent to 1.4 mL/min or 84 mL/hour when reconstituted and diluted per instructions).

   
   

   Paediatric Patients

   
   

   For paediatric patients aged 1 month to < 18 years, the volume of infusion solution required to deliver the dose will vary depending on the weight of the patient. The reconstituted solution must be further diluted to a concentration of 0.77 mg/mL for the final infusion solution. A programmable syringe or infusion pump is recommended. The rate of infusion should not exceed 1.1 mg/minute (equivalent to 1.4 mL/minute or 84 mL/hour when reconstituted and diluted per instructions).

   
   

   1. Calculate patient dose and reconstitute vial(s) required according to reconstitution instructions to provide a concentration of 3.33 mg/mL

      
      

   2. Calculate the volume (mL) of reconstituted anidulafungin required:

      
      

      • Volumeofanidulafungin(mL) = Dose of anidulafungin (mg)  3.33 mg/mL

        
        

   3. Calculate the total volume of dosing solution (mL) required to provide a final concentration of

      1. mg/mL:

         
         

         • Totalvolumeofdosingsolution(mL) = Dose of anidulafungin (mg) ÷ 0.77 mg/mL

   4. Calculate the volume of diluent [5% Dextrose Injection, USP or 0.9% Sodium Chloride Injection, USP (normal saline)] required to prepare the dosing solution:

      
      

      • Volumeofdiluent(mL) = Total volume of dosing solution (mL) – Volume of anidulafungin (mL)

        
        

   5. Aseptically transfer the required volumes (mL) of anidulafungin and 5% Dextrose Injection, USP or 0.9% Sodium Chloride Injection, USP (normal saline) into an infusion syringe or IV infusion bag needed for administration.

For single use only. Waste materials should be disposed of in accordance with local requirements.